Hopp til hovedinnhold

Daklizumab (Zinbryta®)

Publisert:
Sist revidert av:

Kilder

Referanser

  1. Kappos L, Wiendl H, Selmaj K, et al. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. The New England journal of medicine 2015;373:1418-1428 . pmid:26444729 PubMed  
  2. Tramacere I, Del Giovane C, Salanti G, D'Amico R, Filippini G. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. The Cochrane database of systematic reviews 2015:CD011381 . pmid: 26384035 PubMed  
  3. Single Technology Assessment. Zinbryta (daclizumab) – for the treatment of adults with relapsing forms of multiple sclerosis. Statens Legemiddelverk Nye Metoder 2017;ID2015_45:1-42. nyemetoder.no  
  4. Mehta L, Umans K, Ozen G, Robinson RR, Elkins J. .Immune Response to Seasonal Influenza Vaccine in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Long-term Daclizumab Beta: A Prospective, Open-Label, Single-Arm Study. International journal of MS care 2017;19:141-147 . pmid:28603462 PubMed  
  5. Lin YC, Winokur P, Blake A, et al. Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination. Neurology(R) neuroimmunology & neuroinflammation 2016;3:e196 . pmid:26848487 PubMed  
  • Lars Bøe, spesialist i nevrologi, professor Phd
  • Unn Ljøstad, spesialist i nevrologi, professor Phd
  • Åse Mygland, spesialist i nevrologi, professor dr med